Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Assets Average (2020 - 2026)

Kymera Therapeutics (KYMR) has disclosed Assets Average for 7 consecutive years, with $1.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Assets Average rose 79.92% year-over-year to $1.7 billion; the TTM value through Mar 2026 reached $1.7 billion, up 79.92%, while the annual FY2025 figure was $1.4 billion, 75.11% up from the prior year.
  • Assets Average hit $1.7 billion in Q1 2026 for Kymera Therapeutics, up from $1.4 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.7 billion in Q1 2026 and bottomed at $543.2 million in Q2 2022.
  • Average Assets Average over 5 years is $846.5 million, with a median of $722.0 million recorded in 2024.
  • Year-over-year, Assets Average dropped 9.14% in 2023 and then soared 79.92% in 2026.
  • Kymera Therapeutics' Assets Average stood at $620.8 million in 2022, then dropped by 9.14% to $564.1 million in 2023, then surged by 78.42% to $1.0 billion in 2024, then surged by 41.33% to $1.4 billion in 2025, then increased by 19.93% to $1.7 billion in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $1.7 billion, $1.4 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.